Premium
Fertility in males treated for Hodgkins disease with COPP/ABV hybrid
Author(s) -
Hobbie Wendy L.,
Ginsberg Jill P.,
Ogle Susan K.,
Carlson Claire A.,
Meadows Anna T.
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20172
Subject(s) - procarbazine , copp , medicine , fertility , infertility , vincristine , vinblastine , oncology , cyclophosphamide , fertility preservation , prednisone , gynecology , chemotherapy , pregnancy , biology , heme , population , biochemistry , genetics , heme oxygenase , environmental health , enzyme
Abstract More than 80% of those diagnosed with Hodgkins disease (HD) will survive long‐term. For the past decade, a modified hybrid consisting of cyclophosphamide (2.4–3.6g/m 2 ), vincristine, procarbazine, and prednisone (COPP) together with adriamycin, bleomycin, and vinblastine (ABV) has been used to treat patients with HD. Little data exists on how this modified hybrid impacts male fertility. Eleven male patients treated with COPP‐ABV hybrid were studied. Nine out of 11 subjects were categorized as infertile by semen analysis; 7 of 9 were azoospermic. There was no association between fertility status and prepubertal status at diagnosis or gonadotropin status. Despite lower doses of cyclophosphamide, treatment with the current COPP/ABV hybrid leads to infertility in the majority of young men. It is likely that procarbazine, an effective yet potent gonadotoxic agent, is responsible for this outcome. © 2004 Wiley‐Liss, Inc.